Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma-Reply

Ji-Bin Li¹, Zhuo-Chen Lin², Jian-Hua Fu^{1

3}

Affiliations

¹ Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
² Department of Medical Records, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
³ Guangdong Esophageal Cancer Institute, Guangzhou, China.

Comment

Ji-Bin Li et al. JAMA Surg. 2022.

. 2022 May 1;157(5):459-460.

doi: 10.1001/jamasurg.2021.7114.

Ji-Bin Li¹, Zhuo-Chen Lin², Jian-Hua Fu^{1

3}

¹ Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
² Department of Medical Records, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
³ Guangdong Esophageal Cancer Institute, Guangzhou, China.

No abstract available

Comment on

Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J. Yang H, et al. JAMA Surg. 2021 Aug 1;156(8):721-729. doi: 10.1001/jamasurg.2021.2373. JAMA Surg. 2021. PMID: 34160577 Free PMC article. Clinical Trial.
Evaluating Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma.
Sun R, Tian L, Wei LJ. Sun R, et al. JAMA Surg. 2022 May 1;157(5):458-459. doi: 10.1001/jamasurg.2021.7113. JAMA Surg. 2022. PMID: 35080625 No abstract available.